ArticleAdvanced healthcare materials2022
Well-Defined Mannosylated Polymer for Peptide Vaccine Delivery with Enhanced Antitumor Immunity.
Article in Advanced healthcare materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Self-assembled nanoplatforms for cancer immunotherapy: Principles, progress and perspectives.Acta pharmaceutica Sinica. B · 2026Review
- Polymeric Nanoparticles for Precision Tumor Immunotherapy: Rational Design Strategies and Spatiotemporal Immune Activation.International journal of nanomedicine · 2026Review
- Research hotspots and trends in tumor vaccine adjuvants: A bibliometric analysis from 2010 to 2024.Human vaccines & immunotherapeutics · 2025Review
- Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Biomaterials nanoplatform-based tumor vaccines for immunotherapy.Bioactive materials · 2025Review
- Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective.Vaccines · 2024Review
- Engineering customized nanovaccines for enhanced cancer immunotherapy.Bioactive materials · 2024Review
- Nanofluidic delivery implant sustains localization and maximizes efficacy of intratumoral immunotherapy.Nano today · 2024Article
- Polymeric Nanoparticles for Drug Delivery.Chemical reviews · 2024Review
- Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy.ACS central science · 2024Article
- Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines.BME frontiers · 2024Article
- Transcriptional Targeting of Dendritic Cells Using an Optimized HumanInternational journal of molecular sciences · 2023Article
- Advances in Polymeric Micelles: Responsive and Targeting Approaches for Cancer Immunotherapy in the Tumor Microenvironment.Pharmaceutics · 2023Review
- Copolymer Micelles: A Focus on Recent Advances for Stimulus-Responsive Delivery of Proteins and Peptides.Pharmaceutics · 2023Review
- Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- A mannosylated polymer with endosomal release properties for peptide antigen delivery.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Bio-Inspired Drug Delivery Systems: From Synthetic Polypeptide Vesicles to Outer Membrane Vesicles.Pharmaceutics · 2023Review
- Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines.Frontiers in immunology · 2023Review
- Locoregional Lymphatic Delivery Systems Using Nanoparticles and Hydrogels for Anticancer Immunotherapy.Pharmaceutics · 2022Review
- Comprehensive Analysis ofFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Peptide-based cancer vaccines offer production and safety advantages but have had limited clinical success due to their intrinsic instability, rapid clearance, and low cellular uptake. Nanoparticle-based delivery vehicles can improve the in vivo stability and cellular uptake of peptide antigens. Here, a well-defined, self-assembling mannosylated polymer is developed for anticancer peptide antigen delivery. The amphiphilic polymer is prepared by reversible addition-fragmentation chain transfer (RAFT) polymerization, and the peptide antigens are conjugated to the pH-sensitive hydrophobic block through the reversible disulfide linkage for selective release after cell entry. The polymer-peptide conjugates self-assemble into sub-100 nm micelles at physiological pH and dissociate at endosomal pH. The mannosylated micellar corona increases the accumulation of vaccine cargoes in the draining inguinal lymph nodes and facilitates nanoparticle uptake by professional antigen presenting cells. In vivo studies demonstrate that the mannosylated micelle formulation improves dendritic cell activation and enhances antigen-specific T cell responses, resulting in higher antitumor immunity in tumor-bearing mice compared to free peptide antigen. The mannosylated polymer is therefore a simple and promising platform for the delivery of peptide cancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.